Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism

Meyer, Guy; Vicaut, Éric; Danays, Thierry; Agnelli, Giancarlo; Becattini, Cecilia; Beyer‐Westendorf, Jan; Bluhmki, Erich; Bouvaist, Hélène; Brenner, Benjamin; Couturaud, Françis; Dellas, Claudia; Empen, Klaus; Paula Figueirêdo de Montalvão França, Ana; Galiè, Nazzareno; Geibel, Annette; Z. Goldhaber, Samuel; Jiménez, David; Kozak, Matija; Kupatt, Christian; Kucher, Nils; Lang, Iréne; Lankeit, Mareike; Méneveau, Nicolas; Pacouret, G; Palazzini, Massimiliano; Octavian Petriş, Antoniu; Pruszczyk, Piotr; Rugolotto, Matteo; Salvi, Aldo; Schellong, Sebastian; Sebbane, Mustapha; Sobkowicz, Bożena; Stefanović, Branislav; Thiele, Hölger; Torbicki, Adam; Verschuren, Franck; Konstantinides, Stavros

doi:10.1056/nejmoa1302097

Public

Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism

Published in New England Journal of Medicine • Apr 9, 2014

Authors:

Guy Meyer

Éric Vicaut

Thierry Danays

Abstract

BACKGROUND: The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial. METHODS: In a randomized, double-blind trial, we compared tenecteplase plus heparin with placebo plus heparin in normotensive patients with intermediate-risk pulmonary embolism. Eligi...

Subject

Fibrinolysis

Pulmonary embolism

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!